Ivan Poullaos Discusses How the Supreme Court’s Enablement Ruling in Amgen v. Sanofi Will Affect Biologic Patent Portfolio Strategies

Winston & Strawn Partner Ivan Poullaos will speak at the 14^th Summit on Biosimilars & Innovator Biologics, June 27-28, in Boston. The summit—which attracts the “who’s who” of the industry, including leading in-house counsel from branded and biosimilar companies; representatives from key government agencies; and the top patent and regulatory attorneys—will cover legal, regulatory, and commercial strategies for the innovator and biosimilars marketplace.

Ivan’s panel “Amgen v. Sanofi: Anticipating How the Supreme Court’s Enablement Ruling Will Affect Biologic Patent Portfolio Strategies” will discuss:

• Devising alternate strategies for drafting enforceable claims
• Outlining the scope of appropriate claims for antibodies
• Implementing new strategies for drafting enforceable claims in view of the Supreme Court’s decision
• Understanding the nuances between written description and enablement
• Why did the Supreme Court decline to hear Kite v Juno?
• Reconciling whether written description is met when the specification discloses formulas

Learn more and register here.

Learn more about Winston’s Patent Litigation Practice here.